vTv Therapeutics — Third Quarter 2026 Earnings Summary

vTv Therapeutics completed enrollment of 166 participants in its Phase 3 CATT1 trial evaluating cadisegliatin for type 1 diabetes, with topline results expected in mid-2027. The company also randomized the first participant in the Phase 2a Hybrid CATT1 pilot study for patients using hybrid closed-loop insulin delivery systems. In October 2026, the FDA granted Orphan Drug Designation to HPPD, an investigational treatment for sickle cell disease. For the third quarter ended September 30, 2026, the company reported cash and cash equivalents of $77.2 million and a net loss of $11.6 million.